Phase 2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide in Patients With Recurrent Survivin-Expressing Diffuse Large B-Cell Lymphoma (DLBCL)
This phase 2 study is designed to assess the efficacy and safety of DPX-Survivac plus low
dose cyclophosphamide in subjects with recurrent diffuse large B-cell lymphoma (DLBCL) who
are not eligible for transplant.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society